Literature DB >> 23525615

Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance.

Clifford M Takemoto1, Michael B Streiff, Kenneth M Shermock, Peggy S Kraus, Junnan Chen, Jayesh Jani, Thomas Kickler.   

Abstract

We examined the concordance of heparin levels measured by a chromogenic anti-Xa assay and the activated partial thromboplastin time (APTT) during unfractionated heparin therapy (UFH) and the biochemical basis for differences between these measures. We also investigated the endogenous thrombin potential (ETP) as a possible measure of anticoagulation. Paired measures of anti-Xa and APTT were performed on 569 samples from 149 patients on UFH. The anti-Xa values and the APTT were concordant in only 54% of measurements. One hundred twelve samples from 59 patients on UFH were assayed for APTT, anti-Xa, factor II, factor VIII, and ETP. Supratherapeutic APTT values but therapeutic anti-Xa results had decreased factor II activity. Subtherapeutic APTT but therapeutic anti-Xa values had high factor VIII activity. ETP correlated with anticoagulation status and UFH dose. In conclusion, factor II and VIII activity contributes to discordance between APTT and anti-Xa results. ETP measurements may provide an additional assessment of anticoagulation status.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23525615     DOI: 10.1309/AJCPS6OW6DYNOGNH

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  21 in total

1.  Description and Evaluation of the Implementation of a Weight-Based, Nurse-Driven Heparin Nomogram in a Tertiary Academic Medical Center.

Authors:  James W Schurr; Craig A Stevens; Anne Bane; Carol Luppi; Sarah E Culbreth; Amy Leigh Miller; Jean M Connors; Katelyn W Sylvester
Journal:  Clin Appl Thromb Hemost       Date:  2017-08-04       Impact factor: 2.389

2.  Concordance between Activated Partial Thromboplastin Time and Antifactor Xa Assay for Monitoring Unfractionated Heparin in Hospitalized Hyperbilirubinemic Patients.

Authors:  Leana Mahmoud; Andrew R Zullo; Donald McKaig; Christine M Berard-Collins
Journal:  R I Med J (2013)       Date:  2016-03-01

Review 3.  Review of Venoarterial Extracorporeal Membrane Oxygenation and Development of Intracardiac Thrombosis in Adult Cardiothoracic Patients.

Authors:  Brittney Williams; Wendy Bernstein
Journal:  J Extra Corpor Technol       Date:  2016-12

4.  Impact of Protocolized Pharmacist Intervention on Critical Activated Partial Thromboplastin Time Values With Heparin Infusions.

Authors:  Rachelle Barry; Craig A Stevens; Trina Huynh; Dmitri Lerner
Journal:  J Pharm Technol       Date:  2021-07-14

5.  Design and Implementation of an Anti-Factor Xa Heparin Monitoring Protocol.

Authors:  Tanya Williams-Norwood; Megan Caswell; Barbara Milner; Joseph C Vescera; Kelly Prymicz; Amy G Ciszak; Carol Ingle; Christopher Lacey; Evi X Stavrou
Journal:  AACN Adv Crit Care       Date:  2020-06-15

6.  From Activated Partial Thromboplastin Time to Antifactor Xa and Back Again.

Authors:  Jori E May; Rance Chad Siniard; Laura J Taylor; Marisa B Marques; Radhika Gangaraju
Journal:  Am J Clin Pathol       Date:  2022-03-03       Impact factor: 5.400

7.  Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays.

Authors:  Owain Thomas; Emanuel Lybeck; Karin Strandberg; Nahreen Tynngård; Ulf Schött
Journal:  PLoS One       Date:  2015-01-27       Impact factor: 3.240

8.  A Systems Pharmacology Model for Predicting Effects of Factor Xa Inhibitors in Healthy Subjects: Assessment of Pharmacokinetics and Binding Kinetics.

Authors:  X Zhou; Drh Huntjens; Rahj Gilissen
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-10-09

9.  Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy.

Authors:  Jung-Hyun Byun; In-Seok Jang; Jong Woo Kim; Eun-Ha Koh
Journal:  Blood Res       Date:  2016-09-23

10.  Renal Vein Thrombosis in a Newborn With Abnormal Factor VIII Level: Clinical Case Report.

Authors:  Agnieszka Szafranska; Agata Pajak; Katarzyna Kilis-Pstrusinska; Barbara Królak-Olejnik
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.